Kyongbo Pharmaceutical Co Ltd Asset Resilience Ratio
Kyongbo Pharmaceutical Co Ltd asset resilience ratio. Kyongbo Pharmaceutical Co Ltd (214390) has an Asset Resilience Ratio of 1.88% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See 214390 cash and liquid assets coverage to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Kyongbo Pharmaceutical Co Ltd (2017–2025)
Asset resilience ratio of Kyongbo Pharmaceutical Co Ltd from 2017 to 2025. This chart shows how Kyongbo Pharmaceutical Co Ltd's Asset Resilience Ratio has changed over time. Read how much debt does Kyongbo Pharmaceutical Co Ltd carry for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Kyongbo Pharmaceutical Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see 214390 asset base.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 0% |
| Short-term Investments | ₩6.91 Billion | 1.88% |
| Total Liquid Assets | ₩6.91 Billion | 1.88% |
Asset Resilience Insights
- Limited Liquidity: Kyongbo Pharmaceutical Co Ltd maintains only 1.88% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Kyongbo Pharmaceutical Co Ltd Industry Peers by Asset Resilience Ratio
Compare Kyongbo Pharmaceutical Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Jiangsu Nhwa Pharmaceutical Co Ltd
SHE:002262 |
Drug Manufacturers - Specialty & Generic | 26.45% |
|
Tibet Rhodiola Pharmaceutical Holding Co
SHG:600211 |
Drug Manufacturers - Specialty & Generic | 11.84% |
|
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091 |
Drug Manufacturers - Specialty & Generic | 26.36% |
|
Renhe Pharmacy Co Ltd
SHE:000650 |
Drug Manufacturers - Specialty & Generic | 37.54% |
|
Bide Pharmatech Co. Ltd. A
SHG:688073 |
Drug Manufacturers - Specialty & Generic | 9.46% |
|
Jianmin Pharmaceutical Group Co Ltd
SHG:600976 |
Drug Manufacturers - Specialty & Generic | 20.61% |
|
Qianjiang Yongan Pharmaceutical Co Ltd
SHE:002365 |
Drug Manufacturers - Specialty & Generic | 30.38% |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078 |
Drug Manufacturers - Specialty & Generic | 0.42% |
Kyongbo Pharmaceutical Co Ltd Asset Resilience Ratio by Year (2017–2025)
Kyongbo Pharmaceutical Co Ltd asset resilience ratio by year from 2017 to 2025. The table below shows the annual Asset Resilience Ratio data for Kyongbo Pharmaceutical Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 0.26% | ₩820.00 Million ≈ $555.70K |
₩319.54 Billion ≈ $216.55 Million |
-0.45pp |
| 2024-12-31 | 0.70% | ₩2.00 Billion ≈ $1.36 Million |
₩283.89 Billion ≈ $192.39 Million |
+0.38pp |
| 2023-12-31 | 0.33% | ₩870.00 Million ≈ $589.59K |
₩266.31 Billion ≈ $180.47 Million |
-0.03pp |
| 2022-12-31 | 0.36% | ₩870.00 Million ≈ $589.59K |
₩240.54 Billion ≈ $163.01 Million |
+0.85pp |
| 2021-12-31 | -0.49% | ₩-1.16 Billion ≈ $-786.85K |
₩236.98 Billion ≈ $160.60 Million |
-4.26pp |
| 2020-12-31 | 3.77% | ₩9.54 Billion ≈ $6.47 Million |
₩253.24 Billion ≈ $171.62 Million |
+4.21pp |
| 2019-12-31 | -0.44% | ₩-1.05 Billion ≈ $-713.64K |
₩237.82 Billion ≈ $161.17 Million |
+0.27pp |
| 2018-12-31 | -0.71% | ₩-1.58 Billion ≈ $-1.07 Million |
₩221.62 Billion ≈ $150.19 Million |
-0.07pp |
| 2017-12-31 | -0.64% | ₩-1.32 Billion ≈ $-895.45K |
₩204.87 Billion ≈ $138.84 Million |
-- |
About Kyongbo Pharmaceutical Co Ltd
Kyongbo Pharmaceutical Co., Ltd manufactures and sells active pharmaceutical ingredients and finished drugs in South Korea and internationally. The company offers general, cephalosporins, and anti-cancer APIs; prescription drugs, including anesthetic, cardiovascular, digestive, and antibiotics; and OTC drugs. It also provides medical devices, including portable X-ray machine and ultrasonic diagno… Read more